BeiGene Ltd. (49B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeiGene Ltd. (49B) has a cash flow conversion efficiency ratio of 0.013x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€44.08 Million ≈ $51.54 Million USD) by net assets (€3.50 Billion ≈ $4.09 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of BeiGene Ltd. to measure how much of total assets are equity-financed.
BeiGene Ltd. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of BeiGene Ltd. to evaluate the quality of earnings relative to operating cash generation.
BeiGene Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeiGene Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cheniere Energy Partners LP
NYSE MKT:CQP
|
-1.891x |
|
Fomento Económico Mexicano S.A.B. de C.V
MX:FEMSAUBD
|
0.045x |
|
Carpenter Technology Corporation
NYSE:CRS
|
0.094x |
|
AvalonBay Communities Inc
NYSE:AVB
|
0.036x |
|
Bank Hapoalim
TA:POLI
|
0.164x |
|
Everpure, Inc.
NYSE:P
|
0.185x |
|
Tata Steel Limited
NSE:TATASTEEL
|
0.126x |
|
Gold Fields Ltd
JSE:GFI
|
0.264x |
Annual Cash Flow Conversion Efficiency for BeiGene Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of BeiGene Ltd. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 49B stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €3.33 Billion ≈ $3.90 Billion |
€-140.63 Million ≈ $-164.41 Million |
-0.042x | +88.10% |
| 2023-12-31 | €3.54 Billion ≈ $4.14 Billion |
€-1.25 Billion ≈ $-1.47 Billion |
-0.355x | -3.83% |
| 2022-12-31 | €4.38 Billion ≈ $5.12 Billion |
€-1.50 Billion ≈ $-1.75 Billion |
-0.341x | -64.13% |
| 2021-12-31 | €6.24 Billion ≈ $7.30 Billion |
€-1.30 Billion ≈ $-1.52 Billion |
-0.208x | +37.29% |
| 2020-12-31 | €3.87 Billion ≈ $4.52 Billion |
€-1.28 Billion ≈ $-1.50 Billion |
-0.332x | +56.75% |
| 2019-12-31 | €978.36 Million ≈ $1.14 Billion |
€-750.27 Million ≈ $-877.14 Million |
-0.767x | -145.53% |
| 2018-12-31 | €1.75 Billion ≈ $2.05 Billion |
€-547.72 Million ≈ $-640.34 Million |
-0.312x | -1775.86% |
| 2017-12-31 | €684.23 Million ≈ $799.94 Million |
€12.75 Million ≈ $14.91 Million |
0.019x | +107.35% |
| 2016-12-31 | €352.91 Million ≈ $412.59 Million |
€-89.51 Million ≈ $-104.65 Million |
-0.254x | -- |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more